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Objective. Injections for spinal pain have high
failure rates, emphasizing the importance of patient
selection. It is possible that detecting the presence of a
fibromyalgia (FM)–like phenotype could aid in predic-
tion, because in these individuals a peripheral injection
would not address pain due to alterations in central
neurotransmission. We undertook this study to test the
hypothesis that patients who have spine pain meeting
survey criteria for FM would be phenotypically distinct
from those who do not.
Methods. We studied 548 patients diagnosed as
having primary spine pain. All patients completed val-
idated self-report questionnaires, including the Brief Pain
Inventory, the PainDETECT questionnaire, the Hospi-
tal Anxiety and Depression Scale, measures of physical
function, and the FM criteria and severity scales.
Results. Forty-two percent of the patients were
FM positive according to the FM criteria and severity
scales. Compared with FM-negative patients, FM-
positive patients were more likely to be younger, unem-
ployed, and receiving compensation for pain and to have
greater pain severity and pain interference and more
neuropathic pain descriptors as well as higher levels of
depression and anxiety and a lower level of physical
function (P < 0.002 for each comparison). Female sex,
neuropathic pain, pain interference, and anxiety were
independently predictive of FM status in a multivariate
analysis (P < 0.01 for all variables). Receiver operating
characteristic curve analysis showed a strength of asso-
ciation of 0.80 as measured by the cross-validated C
statistic.
Conclusion. Using the FM criteria and severity
scales, we demonstrated profound phenotypic differ-
ences in a population of patients with spine pain.
Although centralized pain cannot be confirmed with a
self-report instrument alone, the pathophysiology of
FM may help explain a portion of the variability of
responses to spine interventions.
Spine pain is one of the most common causes of
disability in the world. It is estimated that 10–15% of the
US population seeks care for low back pain each year
(1). Second only to the treatment of joint pain, spine
pain is considered the most expensive musculoskeletal
condition; estimates exceed $140 billion in annual lost
wages and treatment costs (1,2). Recently, there has
been an explosion in the use of minimally invasive
therapies for the treatment of spine pain. Between 1997
and 2006 in the Medicare population, facet joint inter-
ventions increased by 543% (3), and epidural steroid
injections increased by 102% (4). These and other mini-
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mally invasive therapies have high failure rates, implying
that patient selection may play a crucial role (5,6).
Some patient risk factors predictive of poor out-
comes from epidural steroid injections and facet joint
interventions include long duration of pain, opioid
consumption, previous spine surgery, younger age, in-
creased pain sensitivity, depression, and anxiety (5,7–
12). Similarly, pain in other locations, depression, catas-
trophizing, and somatization all have been described as
predictors of lesser analgesic response from lower ex-
tremity joint arthroplasty (13). It is possible that this
collection of patient risk factors can be explained by a
common pathophysiologic mechanism. There is a grow-
ing appreciation of the importance of augmented central
nervous system (CNS) processing of pain and other
symptoms in several chronic pain states (14). Such states
lack clear peripheral pathology and have been given
specific names, including fibromyalgia (FM), irritable
bowel syndrome, and interstitial cystitis (14–17). Argu-
ably the best studied of these, FM, is characterized by
widespread body pain and comorbid symptoms (e.g.,
fatigue, trouble thinking, depression) without apparent
peripheral pathology. Instead, pain sensitivity and neu-
ropathic pain symptoms have been associated with alter-
ations in central neurotransmission (15,18–22).
Experimental pain testing and functional neuro-
imaging studies have shown that subsets of individuals
with classically described “peripheral” pain conditions,
such as osteoarthritis and rheumatoid arthritis, demon-
strate patterns of augmented CNS pain processing sim-
ilar to those seen in conditions like FM, and thus po-
tentially have a component of “centralized pain” (23,24).
The few experimental studies conducted in spine pain
support the same conclusion. Pain threshold has been
shown to be a robust predictor of pain response and
physical function (25), and functional magnetic reso-
nance imaging in low back pain has demonstrated
patterns of augmented central pain processing similar to
those seen with FM (26). However, the frequency of
“centralized pain” in a population of patients with spine
pain is not known.
In 2011, FM criteria and severity scales (also
known as survey criteria for FM) were introduced for
use in clinical and epidemiologic studies (27). The FM
criteria and severity scales rely on the completion of a
self-report questionnaire and, like the American College
of Rheumatology (ACR) preliminary diagnostic criteria
introduced in 2010 (28), do not require a tender point
examination (27). The aim of the present study was to
determine whether the FM criteria and severity scales
could differentiate patients with spine pain in terms of
measures of pain, affect, and function. FM is rarely
diagnosed in this population, and patients are generally
treated as having pain that is predominantly or solely
due to peripheral pathology of the spine. We hypothe-
sized that patients characterized as FM positive accord-
ing to the FM criteria and severity scales (27–29), which
were used as a surrogate of centralized pain in this study,
would report pain that is more neuropathic in nature
and would have higher levels of pain, depression, anxi-
ety, and disability than those not meeting FM criteria.
The clinical implications of this would be that a brief
self-report measure (e.g., the FM criteria and severity
scales) could eventually be used to guide patient selec-
tion for various interventions based in part on underly-
ing pain mechanisms.
PATIENTS AND METHODS
Approval was obtained from the Institutional Review
Board of the University of Michigan, Ann Arbor. We included
new patients (age 18 years) presenting to the University of
Michigan Back and Pain Center (Department of Anesthesiol-
ogy) from November 2010 to March 2012. As previously de-
scribed (30), all new patients presenting for treatment at our
academic outpatient pain clinic complete an intake packet
that includes validated self-report measures of pain, psycho-
logical status, physical function, and demographic information
(including age, sex, race, ethnicity, marital status, employment
status, and compensation for pain, as reported by the patient
from a predefined list). A coversheet for the intake packet ex-
Table 1. Diagnostic codes included in the study*
Location, diagnosis
ICD-9
code n Percent
Neck and upper extremities
Cervicalgia, neck 723.1 84 15.3
Facet arthropathy cervical or spondylosis
without myelopathy cervical
721 12 2.2
Degenerative disc cervical 722.4 3 0.5
Radiculopathy cervical or cervical-
radiculitis/neck
723.4 7 1.3
Spondylosis with myelopathy cervical 721.1 1 0.2
Postlaminectomy syndrome cervical 722.81 2 0.4
Spinal stenosis cervical 723 3 0.5
Middle back
Thoracic spine–middle back 724.1 26 4.7
Herniated nucleus pulposus–thoracic 722.11 0 0.0
Low back and lower extremities
Low back/lumbago 724.2 269 49.1
Degenerative disc lumbar 722.52 11 2.0
Facet arthropathy lumbar or spondylosis
without myelopathy lumbosacral
721.3 13 2.4
Herniated nucleus pulposus lumbar 722.1 17 3.1
Radiculopathy thoracic/lumbar 724.4 30 5.5
Spinal stenosis lumbar 724.02 27 4.9
Postlaminectomy syndrome lumbar 722.83 32 5.8
Sacroiliac joint dysfunction 739.4 9 1.6
Sacroiliitis 720.2 2 0.4
Total – 548 –
* Spine pain was defined by the primary diagnosis assigned by the
treating physician using the International Classification of Diseases,
Ninth Revision (ICD-9) codes during the new patient encounter.
3286 BRUMMETT ET AL
plains that the information will be used for clinical care and
research, and a waiver of written informed consent was ob-
tained from the Institutional Review Board. The International
Classification of Diseases, Ninth Revision (ICD-9) code as-
signed by the treating physician was used to define the spine
pain cohort. Disorders of the axial neck, middle and low back,
or surrounding spine structures, as well as radicular pain and
results of failed spine surgery, were all included (Table 1). A
3-month audit of the number of new patients evaluated, with
phenotyping included in the data set, demonstrated that data
were captured for 85.7% of the patients (data not shown).
Instruments used to evaluate patients. The FM criteria
and severity scales consist of an assessment of widespread pain
and symptom severity (27,28). The Widespread Pain Index
(WPI) was calculated using the Michigan Body Map (31) to
assess the 19 specific body areas described in the FM criteria
and severity scales (score 0–19). Symptom severity was evalu-
ated using the Symptom Severity (SS) scale (score 0–12). As
per the FM survey criteria, patients were classified as FM
positive if their scores were WPI 7 and SS 5 or WPI 3–6
and SS 9. The validity of the FM criteria and severity scales
has been established, both when compared with the 1990
ACR classification criteria (which include the tender point
examination) (29,32) and when compared with the 2010 ACR
preliminary diagnostic criteria (which include physician’s as-
sessment) (28,33). Patients missing FM criteria and severity
scales data were excluded from analysis. Additional phenotyp-
ing measures were completed/recorded, including the Brief
Pain Inventory (BPI) (pain intensity and interference) (34),
the PainDETECT questionnaire (neuropathic pain) (35),
the Oswestry Disability Index (ODI) (physical function) (36),
the Patient-Reported Outcomes Measurement Information
System (PROMIS) Physical Function Short Form 1 (physical
function) (37), the Hospital Anxiety and Depression Scale
(HADS) (symptoms of depression and anxiety) (38), and the
duration of pain.
Statistical analysis. Data were entered into the Assess-
ment of Pain Outcomes Longitudinal Electronic Data Capture
system (30). Missing data for the validated instruments were
handled as described by authors of the instruments (35,38,39).
Table 2. Univariate analyses of differences between the groups*
FM-negative
(n  257)
FM-positive
(n  186) P
FM criteria and severity scales score 8.46  2.79 17.2 3.89 0.0001
Demographics
Age, years 51.9  17.5 46.9  13.6 0.001
Female, % 54.1 59.1 0.29
Caucasian, % 89.2 85.2 0.22
College education, % 46.0 45.3 0.89
Married, % 59.6 53.8 0.23
Employed, % 41.2 25.4 0.0005
Receiving compensation for pain, % 18.1 33.1 0.0005
Type of compensation, % 0.20
Social security 51.2 56.4
Long-term disability 7.3 10.9
Workers’ compensation 14.6 9.1
Sick leave 12.2 1.8
No-fault insurance 14.6 21.8
Pain phenotype
Pain severity (BPI) 6.02  1.83 7.2  1.54 0.0001
Pain interference (BPI) 6.33 2.11 7.95  1.69 0.0001
Neuropathic pain descriptors (PainDETECT questionnaire) 14 7.85 22.1  7.79 0.0001
Physical function (ODI) 40.3  16.6 55.3 15.8 0.0001
Physical function (PROMIS Physical Function Short Form 1) 31.9  7.42 26.9  7.81 0.0001
Anxiety (HADS) 6.61 3.67 11.7  4.65 0.0001
Depression (HADS) 7.15 4.23 11.5  4.4 0.0001
Duration of pain, % 0.0096
3 months 8.1 1.0
3–6 months 11.4 3.1
7–12 months 12.2 12.5
1–5 years 35.0 42.7
5 years 33.3 40.6
* Except where indicated otherwise, values are the mean SD. The fibromyalgia (FM) criteria and
severity scales score ranges from 0 to 31. The Brief Pain Inventory (BPI) measures pain intensity (mean
score of 4 questions regarding current, worst, least, and average pain intensity over last 7 days, from 0 to
10, where 0  no pain and 10  worst pain imaginable) and pain interference (mean score of the 7
interference questions of the BPI, from 0 to 10, where 0  does not interfere and 10  totally interferes).
The PainDETECT questionnaire measures neuropathic pain on a scale of 1 to 38, where higher scores
indicate more neuropathic pain. The Oswestry Disability Index (ODI) ranges from 0 to 100, where a
higher score indicates more disability. The Patient-Reported Outcomes Measurement Information System
(PROMIS) Physical Function Short Form 1 ranges from 10 to 50, where lower scores indicate lower
physical function. The Hospital Anxiety and Depression Scale (HADS) ranges from 0 to 21, where higher
scores indicate more anxiety and more symptoms of depression.
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As noted above, patients who did not complete all the com-
ponents of the FM criteria and severity scales were not in-
cluded in the analysis. Additionally, patients missing more than
1 item on the BPI subscales, PainDETECT questionnaire,
and ODI were excluded. The PROMIS Physical Function
Short Form 1 requires complete data on all 10 items, so
patients missing any items were excluded. For the HADS,
when 6 of the 7 questions were answered, a single value for the
missing item was inferred by imputation of the mean of the
other 6 values as recommended. For the other instruments,
only 1 missing question was allowed; however, other completed
questionnaires were allowed (i.e., patients were not completely
excluded from the analysis for having 1 incomplete question-
naire).
Data were analyzed using R software, version 2.15.0
(www.r-project.org) and SPSS software, version 19. Between-
group comparisons were performed using a t-test for continu-
ous variables, a chi-square test for binary variables, and a
Wilcoxon test for ordered categorical variables. The signifi-
cance level was set at 0.025 to account for the previous analysis
on a smaller data set conducted for the presented abstract. We
studied patterns of association between the observed pheno-
type, and their relationship with the centralized pain pheno-
type, using binary categorization of FM status by the previ-
ously described FM criteria and severity scales (FM positive
versus FM negative) (27,28) and the continuous “fibromyalgia-
ness” score (the sum of the WPI and SS scales). Multivariate
linear regression was used to study association between the
continuous FM score and measured phenotype and pain
variables. Association of the phenotype and pain variable
panel with the binary FM status was analyzed using logistic
regression. Best model selection using Akaike’s information
criterion (AIC) and likelihood ratio tests was used to select the
best set of predictor variables. Prediction strength of the
logistic model was analyzed using a receiver operating charac-
teristic (ROC) curve. The ROC curve analysis was cross-
validated (10-fold) to ensure reproducibility of predictions and
avoid model overfitting. Cross-validated estimate of the area
under the ROC curve (C statistic) was used to characterize the
predictive performance of the phenotype and pain profile with
respect to the FM categorization (FM positive or FM nega-
tive). Model adequacy was tested using a variety of standard-
ized residual plots (not shown).
Radicular pain and spinal stenosis are frequently asso-
ciated with neuropathic pain symptoms and are often differ-
entiated from axial spine pain. In order to specifically analyze
the portion of the cohort with axial spine pain (neck pain,
middle back pain, and low back pain), the multivariate analyses
noted above were repeated after excluding patients with
radicular or non–axial spine pain disorders (excluded ICD-9
codes 723.4 [cervical radiculopathy], 721.1 [cervical spondylo-
sis], 722.81 [postlaminectomy syndrome cervical], 723 [cervical
spinal stenosis], 722.11 [thoracic herniated nucleus pulposus],
722.1 [lumbar herniated nucleus pulposus], 724.4 [thoracic or
lumbar radiculopathy], 724.02 [lumbar spinal stenosis], 722.83
[lumbar postlaminectomy syndrome], 739.4 [sacroiliac joint
dysfunction], 720.2 [sacroiliitis]; total n  130) (Table 1).
RESULTS
A total of 1,208 new patients were seen in the
pain clinic over the defined time period, with diag-
noses of primary spine pain in 548 patients. After ex-
clusion of patients who did not have complete data for
the FM criteria and severity scales, 443 patients were
retained for the analysis (Table 2). Of these patients, 186
(42%) were FM positive according to the FM criteria
and severity scales. In univariate analyses, FM-positive
patients were younger (P  0.001), less likely to be em-
ployed (P  0.0005), and more likely to be receiving
compensation for their pain (P 0.0005), but there were
no other significant differences between the 2 groups
with respect to demographic variables (Table 2). Com-
pared to FM-negative patients, FM-positive patients
were more likely to have pain of a longer duration (P 
0.0096) and had higher scores on measures of pain
severity, pain interference, and neuropathic pain (P 
0.0001). FM-positive patients also reported lower phys-
ical function and showed higher levels of anxiety and
more symptoms of depression (P  0.0001).
The multivariate analyses of the associations
between the observed demographic and pain/mood/
function phenotype and both the continuous FM score
and the binary FM classification are shown in Table 3.
FM status (positive versus negative) could be best
predicted using neuropathic pain (the PainDETECT
questionnaire), physical function (the ODI), anxiety (the
HADS), and compensation for pain, with a high area
under the ROC curve (C statistic, area under the curve
[AUC]  0.80). The best model search using AIC
resulted in the same model as the cross-validated ROC
Table 3. Multivariate analysis of the association between pain and
phenotypic variables and FM status*
Model, predictor variable Estimate SE P
Linear
Intercept 2.711 0.765 0.0004
Sex (male vs. female) 1.567 0.422 0.0002
Physical function (ODI) 0.028 0.018 0.12
Pain interference (BPI) 0.432 0.152 0.0047
Neuropathic pain (PainDETECT
questionnaire)
0.129 0.030 0.0001
Anxiety (HADS) 0.412 0.051 0.0001
Logistic
Intercept 4.672 0.518 0.0001
Neuropathic pain (PainDETECT
questionnaire)
0.069 0.018 0.0002
Physical function (ODI) 0.021 0.009 0.024
Anxiety (HADS) 0.221 0.034 0.0001
Compensation for pain 0.485 0.299 0.11
* Measured as a continuous score (linear regression) or dichotomized
(logistic regression) using the FM criteria and severity scales. The best
models after variable selection are presented. See Table 2 for defini-
tions.
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curve analysis (Figure 1). Multivariate prediction of the
FM score as a continuous score reported a similar set of
highly significant best model predictors: sex (male versus
female), pain interference (the BPI), neuropathic pain,
and anxiety (P  0.005 for each significant predictor)
(Table 3).
A subanalysis of the portion of the cohort with
axial spine pain was conducted, which resulted in a re-
duction in the number of patients (n  418) available
for the analysis (see statistical analysis section in Patients
and Methods for additional details). Descriptive between-
group analysis in the subset of patients with axial spine
pain yielded an outcome very similar to that shown in
Table 1 (not shown). The smaller sample size resulted in
a reduced panel of pain and phenotype variables in the
trimmed multivariate models. Pain interference, neuro-
pathic pain, and anxiety were the best predictors after
variable selection using linear (continuous FM status)
and logistic (binary FM status) models (P 0.001 for all
variables). The analysis yielded almost the same AUC
(C statistic) of 0.81 (not shown).
DISCUSSION
We found that 42% of the patients presenting to
a tertiary care facility with a primary diagnosis of spine
pain had FM according to the FM criteria and severity
scales, which suggests the presence of centralized pain.
To our knowledge, this is the first time that the FM
criteria and severity scales have been used to differenti-
ate a spine pain cohort. FM-positive patients reported a
strikingly different pain phenotype from FM-negative
patients (i.e., in univariate analyses the former were
more likely to be female, younger, unemployed, receiv-
ing compensation for their pain, reporting greater pain
intensity and interference, anxious, depressed, using
neuropathic pain descriptors, and reporting diminished
functioning) (Table 2). Analyzing the groups using the
FM criteria and severity scales score as a dichotomous
(logistic) or continuous (linear) measure further demon-
strated that neuropathic pain descriptors, anxiety, pain
interference, and physical function were independently
predictive of the FM criteria and severity scales score
(Table 3), which is consistent with what has previously
been described in patients diagnosed as having FM
using the 1990 ACR classification criteria (32). The
independent predictors from the multivariate models
are some of the most commonly described predictors of
poor outcomes in minimally invasive spine interventions
and postsurgical pain. Hence, there may be a common
underlying pathophysiology or “diagnosis” driving these
findings.
The diagnosis of FM has been a point of contro-
versy for years in the community of pain specialists, as
there is no definitive diagnostic test. FM positivity ac-
cording to the FM criteria and severity scales does not
confirm categorical diagnosis. Instead, according to the
2012 Canadian Guidelines for the diagnosis and manage-
ment of fibromyalgia syndrome (http://www.canadian
painsociety.ca/pdf/Fibromyalgia_Guidelines_2012.pdf),
the taking of a history, a physical examination, and
laboratory testing (e.g., blood count, erythrocyte sedi-
mentation rate, C-reactive protein, creatine kinase, and
thyroid-stimulating hormone) by an experienced pro-
vider are required to make the diagnosis of FM. How-
ever, comorbid FM is common in nearly all other
musculoskeletal chronic pain conditions, including osteo-
arthritis and rheumatoid arthritis (estimates range from
20% to 30%) (23,24). The validity of the FM criteria
and severity scales has been established, both when
compared with the 1990 ACR classification criteria
(which include the tender point examination) (29,32)
and when compared with the 2010 ACR preliminary
diagnostic criteria (which include physician’s assess-
ment) (28,33). As was previously recommended, the
present study applied this validated self-report measure
in an epidemiologic manner to detect widespread body
pain and comorbid symptoms.
Figure 1. Receiver operating characteristic curve for predicting fibro-
myalgia (FM) status (according to the FM criteria and severity scales)
using a panel of demographic, pain, and other phenotypic predictor
variables. CV  cross-validated; Sens.  sensitivity; Spec.  specific-
ity; PV  positive predictive value; PV  negative predictive
value; est.  estimate; s.e.  standard error; dd[, RName]  response
(FM vs. FM).
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These data and those from experimental studies
(26,40,41) suggest that centralized pain may be very
common in spine pain. For example, 2 studies have
shown that a sizable proportion of individuals with
chronic low back pain display diffuse tenderness (e.g.,
mechanical hyperalgesia) and have functional magnetic
resonance imaging findings consistent with FM or simi-
lar centralized pain states (25,26). Using the 4-quadrant
pain described in the 1990 ACR classification criteria
for FM, a retrospective study showed that female pa-
tients with higher pain severity, a family history of
chronic widespread pain, and more painful comorbidi-
ties were more likely to transition from neck and back
pain to chronic widespread pain (42). In the present
study, independent predictors of FM positivity according
to the FM criteria and severity scales included female
sex, higher levels of neuropathic pain descriptors, anxi-
ety, more pain interference, and lower levels of physical
function (Table 3). Neuropathic pain descriptors in
particular are thought to be strongly associated with the
FM pain phenotype and have been shown to correlate
with the number of tender points and pain sensitivity
during experimental pain testing (20,21). Because radic-
ular pain would be expected to present with more
neuropathic pain symptoms, the analyses were also
repeated after excluding radicular pain and non–axial
spine pain diagnoses, and the results did not change.
Most axial spine pain diagnoses (e.g., facet arthro-
pathy, lumbago) are not normally thought to be associ-
ated with high levels of neuropathic pain, yet among
FM-positive patients according to the FM criteria and
severity scales, the mean value for the PainDETECT
measure exceeded the instrument’s defined cut point
for neuropathic pain—with or without including patients
with radicular pain diagnoses (35). Although patients in
different diagnostic groups who meet the criteria for
neuropathic pain using the PainDETECT questionnaire
certainly describe similar levels of pain, the phenotype of
FM-positive patients according to the FM criteria and
severity scales is distinct.
The finding that many patients with spine pain
report widespread body pain and comorbid symptoms,
such as fatigue, trouble thinking, anxiety, and/or de-
pression, could have important treatment implications
and may explain a portion of the high failure rates
described for some of the most common spine interven-
tions. Injections and peripherally targeted analgesics
would be expected to provide less benefit in a patient
with altered central pain processing than in those with
predominantly peripheral pathology. FM is associated
with lower levels of neurotransmitters that inhibit pain,
including norepinephrine, serotonin, and -aminobutyric
acid, along with higher levels of neurotransmitters that
increase pain, including glutamate (15,43). FM patients
also have lower endogenous opioid receptor binding
availability and high levels of cerebrospinal fluid opioids
(44), together suggesting that the endogenous opioid
system is already activated in FM and thus perhaps ex-
plaining the anecdotal experience that opioids are inef-
fective in most of these patients (45).
The use of minimally invasive interventions for
spine pain, such as epidural steroid injections and facet
joint interventions, has increased dramatically in recent
years (3). A recent well-publicized meta-analysis has
called into question the long-term efficacy of epidural
steroid injections (46), and studies of response predic-
tion estimate rates of treatment failure to be between
25% and 45% (47–49). Similarly, although the efficacy
of facet joint interventions has been established in tightly
selected patient populations (50,51), higher failure rates
(39–47%) have been shown in retrospective studies
(5,6), and effectiveness in standard clinical care is not
known. Back and neck pain are frequently described in
FM, and it is possible that the high failure rate for these
interventions is in part due to intervention on a peri-
pheral target in the spine when the nature of the
patient’s pain is due at least in part to brain and spinal
cord dysfunction. Taken together, these data make a
compelling case for the study of a modified treatment
approach. For example, previous studies have demon-
strated efficacy of serotonin-norepinephrine reuptake
inhibitors in chronic low back pain (52). Nonpharmaco-
logic interventions, such as cognitive behavioral therapy
and exercise, have also demonstrated excellent effect
sizes that often exceed those of pharmacologic interven-
tions in FM and other pain states (53).
This study was conducted at a single large, ter-
tiary care pain clinic, and these results may not be
generalizable. The present study is largely hypothesis
generating as it is cross-sectional in nature. Despite the
profound phenotypic differences demonstrated, addi-
tional research is needed to evaluate the presence of
centralized pain (e.g., quantitative sensory testing, neu-
roimaging) and then to better understand the impact of
centralized pain on treatment outcomes. Prospective
studies are required to examine whether some of the
outcome measures used herein are better than a de-
tailed history and physical examination and review of
radiographic findings at predicting which patients with
axial pain will respond best to peripherally directed
procedures, regardless of “diagnosis” (e.g., lumbago,
facet joint arthropathy). As with any data set, this study
was limited by the variables included in the patient-
completed phenotype assessment.
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New patients presenting to a tertiary care pain
clinic with a diagnosis of primary spine pain are com-
monly determined to have FM according to the FM
criteria and severity scales, indicating that more wide-
spread pain is present along with a constellation of
associated symptoms that are presumed to be largely
due to alterations in central neurotransmission. In the
present study, patients with spine pain who were FM
positive according to the FM criteria and severity scales
described profound phenotypic differences from those
who were FM negative, including more neuropathic pain
descriptors, higher levels of anxiety symptoms, greater
pain interference, and lower physical functioning. These
factors largely overlap with those found to be predictive
of poor outcomes in spine pain interventions. It is
possible that a simple self-report measure could aid in
the prediction of outcomes of some of the most common
minimally invasive spine interventions.
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